Stewart Laboratory: Mechanopharmacology

Researcher

Research Overview

About Professor Alastair Stewart

Professor Alastair Stewart has extensive experience in the field of respiratory and inflammation research. He has published over 200 papers, has had numerous patents proceed to grant and has served on various peer review committees for the NHMRC and the scientific advisory boards of several Australian Medical Research Institutes.  Professor Stewart currently Chairs the Therapeutic Technologies Research Initiative (TTRI) at the The University of Melbourne; is Co-Director of the Lung Health Research Centre (LHRC);; and is the Director of the national ARC Industry Transformation Training Centre for Personalised Therapeutics Technologies (ARC CPTT). He is Vice President of the Asia Pacific Federation of Pharmacologists and a member of the Nominating and Programming Committees of the Respiratory Structure Function assembly of the American Thoracic Society.  His editorial roles include Chief Editor of the Translational Pharmacology section of Frontiers in Pharmacology and Senior Associate Editor of the American Society for Mechanical Engineering Journal (ASME), Journal of Engineering and Science in Medical Diagnostics and Therapy. Prof Stewart is developing and applying the concept of mechanopharmacology in drug discovery and ultra-high content screening.

The laboratory conducts, translational and contract research and consultancies.

Laboratory Overview

The Mechanopharmacology Lab is investigating inflammation and fibrosis mechanisms using novel bioassays for drug discovery and characterisation.  A range of systems pharmacology-based analytical approaches are applied using transcriptomic and proteomic data from well-qualified clinical and experimental specimens.  The lab has extensive links to Biomedical Engineering, Chemistry and Physics and strong connections to TTRI, LHRC and ARC-ITTC (Personalised Therapeutic Technologies).

Current projects include:

  • Glucocorticoid sensitivity in structural cells of the airway using Air Liquid Interface Culture.
  • Regulation of mesenchymal cell growth, differentiation and function.
  • Anti-remodelling activity of currently used and potential anti-asthma agents.
  • Impact of extracellular matrix components on the efficacy of anti-remodelling agents.
  • Role of circadian mechanisms in inflammation and tissue remodelling.

Project details may be found on the individual research project pages.

The Mechanopharmacology Lab offers opportunities for placement for BScHons, Masters and PhD candidates and provides a supportive interdisciplinary environment, staffed with highly experienced scientists able to foster translational research goals. Inquiries are welcome.

News from Mechanopharmacology Lab.

Staff

Personnel from Stewart Lab

Researchers

Dr Connie Xia, NHMRC Peter Doherty Research Fellow
Dr Philippe LaChapelle, Visiting Respiratory Fellow
Ms Shenna Langenbach, Senior Research Assistant
Ms Trudi Harris, Senior Research Assistant
Ms Meina Li, PhD Student
Ms Danica Radojicic, PhD Student
Mr Asres Mitke, PhD Student
Mr Fernando Guzman, PhD Student
Ms Asmaa Radwan, PhD Student
Ms Qianyu Chen, PhD Student
Mr Yanqi Wu, PhD Student
Ms Yan Tu, PhD Student
Ms Aakriti Sharma, BSc Hons student

Staff

Dr Maria Bellesis (LHRC)
Dr Susan Northfield (TTRI)
Dr Narelle Tunstall (ARC CPTT)

Collaborators

The University of Melbourne
Dr Jon Mangum, Department of Pharmacology & Therapeutics
Dr Graham Mackay, Department of Pharmacology & Therapeutics
Professor Peter Lee, Biomedical Engineering
Dr Sarah Londrigan, Microbiology and Immunology, Peter Doherty institute
Dr David Simpson, School of Physics
Professor Lloyd Hollenberg, School of Physics
Professor Spencer Williams, School of Chemistry, The University of Melbourne

External collaborators
Professor Jo Douglass, Clinical immunology and Allergy, The Royal Melbourne Hospital
Associate Professor Glen Westall, AIRMed, The Alfred Hospital
Dr Jin-Ah Park, Harvard TH Chan School of Public Health, USA
Professor Martina Schmidt, University of Groningen, The Netherlands
Dr Michael Schuliga, University Newcastle, NSW

Funding

The Laboratory receives funding from the following bodies:

  • ARC
  • NHMRC
  • Asthma Australia
  • CSL

Research Publications

For a full list of publications go to Professor Stewart's ‘Find an Expert’ profile.

2017

  • Qin CX, May LT, Li R, Cao N, Rosli S, Deo M, Alexander AE, Horlock D, Bourke JE, Yang YH, Stewart AG, Kaye DM, DuX-J , Sexton PM, Christopoulos A, Gao X-M, Ritchie RH. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice.  Nature Communications  2017;8:14232 doi: 10.1038/ncomms14232.
  • Schuliga M, Jaffar J, Berhan A, Langenbach S, Harris T, Waters D, Lee PVS, Grainge C, Westall G, Knight D, G. Stewart AG. Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity.  American Journal of Physiology - Lung Cellular and Molecular Physiology 2017;312 doi: 10.1152/ajplung.00553.2016
  • Tu Y, Johnstone CN, Stewart AG. Annexin Al influences in breast cancer: Controversies on contributions to tumour, host an immunoediting processes.  Pharmacological Research 2017;119 doi:10.1016/j.phrs.2017.02.011
  • Stewart AG. Translational Pharmacology. Frontiers in Pharmacology – Translational Pharmacology. 2017 doi: 10.3389/fphar.2017.00008
  • Xia YC,  Radwan A, Keenan CR, Langenbach SY, Li M, Radojicic D, Londrigan SL, Gualano RC, Stewart AG. Glucocorticoid insensitivity in virally infected airway epithelial cells is dependent on transforming growth factor- β activity. PLOS Pathogens 2017 doi: 10.1371/journal.ppat.1006138.
  • Fietz ER, Keenan CR, Campos GL, Tu Y, Johnstone CN, Harris T, Stewart AG. Glucocorticoid resistance of migration and gene expression in a daughter MDA-MB-231 breast tumour cell line selected for high metastatic potential. Scientific Reports 2017;7:43774 doi:10.1038/srep43774
  • Schuliga M, Jaffar J, Berhan A, Westall G, Knight D, Stewart AG.The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF.  Scientific Reports 2017;7:41770. doi: 10.1038/srep41770.
  • Qiao Y, Tam JKC, Tan SSL, Tai YK, Chin CY, Stewart AG, Ashman L, Sekiguchi K, Langenbach SY, Stelmack G, Halayko AJ, Tran T.  Melbourne Epidemiological Study of Childhood Asthma group. CD151, a laminin receptor showing increased expression in asthma, contributes to airway hyperresponsiveness through calcium signaling. J Allergy Clinical Immunology 2017;139(1):82-92.e5 doi: 10.1016/j.jaci.2016.03.029.
  • Perret JL, Plush B, Lachapelle P, Hinks TSC, Walter C, Clarke P, Irving L, Brady P, Dharmage SC, Stewart AG. Coal mine workers’ lung disease in the modern era. Respirology 2017;22:662-670.

2016

2015

Research Projects

This Research Group doesn't currently have any projects



Faculty Research Themes

Infection and Immunology

School Research Themes

Infection & Immunity, Therapeutics & Translation



Key Contact

For further information about this research, please contact Head of Laboratory Professor Alastair Stewart

Department / Centre

Pharmacology and Therapeutics

Unit / Centre

Stewart Laboratory: Mechanopharmacology


MDHS Research library
Explore by researcher, school, project or topic.